37041-32-0

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 4-CHLORO-8-METHYLQUINOXALINE-3-CARBOXYLATE is used as a building block for the synthesis of various bioactive molecules and pharmaceutical drugs due to its potential medicinal properties. It contributes to the development of new therapeutic agents by providing a structural foundation that can be further modified or combined with other compounds to enhance their pharmacological effects.
Used in Drug Discovery and Development:
In the realm of drug discovery and development, ETHYL 4-CHLORO-8-METHYLQUINOXALINE-3-CARBOXYLATE is employed as a key component in the creation of novel drug candidates. Its unique structure allows for the exploration of its interactions with biological targets, potentially leading to the discovery of new treatments for various diseases and conditions.
Used in Research and Development Studies:
ETHYL 4-CHLORO-8-METHYLQUINOXALINE-3-CARBOXYLATE is also utilized in research and development studies to investigate its potential biological activities. This includes examining its interactions with cellular and molecular targets, as well as assessing its efficacy and safety in preclinical models. Such studies are essential for understanding the compound's therapeutic potential and guiding its further development as a pharmaceutical agent.

InChI:InChI=1/C13H12ClNO2/c1-3-17-13(16)10-7-15-12-8(2)5-4-6-9(12)11(10)14/h4-7H,3H2,1-2H3

Upstream product

• 77156-75-3 4-hydroxy-8-methyl-quinoline-3-carboxylic acid ethyl ester 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 95-53-4 o-toluidine 
• 77156-75-3 ethyl 1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylate 
• 19146-73-7 diethyl 2-((o-tolylamino)methylene)malonate 

Downstream Products

• 206258-78-8 4-[benzyl-(4-methoxy-benzenesulfonyl)-amino]-8-methyl-quinoline-3-carboxylic acid ethyl ester 
• 206258-79-9 4-[benzyl-(4-methoxy-benzenesulfonyl)-amino]-8-methyl-quinoline-3-carboxylic acid 

Relevant academic research and scientific papers

Structural evaluation of three 2-phenylpyrazolo[4,3-c]quinolin-3-one monohydrates

A single crystal X-ray diffraction and theoretical study has been carried out on mono hydrates of three 2H-pyrazolo[4,3-c]quinolin-3(5H)-one derivatives, namely 6-methyl-2-phenylpyrazolo[4,3-c]quinolin-3-one, 3, 6-methyl-2-(4- chlorophenyl)pyrazolo[4,3-c]quinolin-3-one, 4, and 8-methyl-2-(4-nitrophenyl) pyrazolo[4,3-c]quinolin-3-one, 5. The monohydrates were obtained on recrystallization from moist solvents. While there are three tautomeric forms possible for such pyrazolo[4,3-c]quinolin-3-one molecules, the sole form isolated in the solid [(X)×(H2O)] (X = 3, 4 and 5) compounds was the quinoloid form - the one calculated to be the most stable at the M06-2X/6-311++G(d,p) level of theory. Excellent agreement was found between the calculated and X-ray determined structures. Molecule 5 in [(5)×(H 2O)] is very near planar while both molecules 3 and 4 in their respective hydrates are much less so as a consequence of angles about 24 between the two aromatic rings. In each hydrate, the pyrazolo[4,3-c]quinolin-3-one molecule is bonded to three water molecules and each water molecule is likewise H-bonded to three pyrazolo[4,3-c]quinolin-3-one molecules. While the water molecules are H-bonded to 3 and 4 via the pyridinyl N and 2x the carbonyl O atoms, in [(5)×(H2O)] the H-bonds are to pyridinyl N, carbonyl O and a nitro O atoms. Calculations indicated that the found arrangement in [(5)×(H2O)] is more stable than one using the connections as found in [(3)×(H2O)] and [(4)×(H2O)]. While each of the hydrates possess strong N-H?O and O-H?O hydrogen bonds, and weaker C-H?π and π?π interactions, the supramolecular arrays are very different.

Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors

Potent and selective bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors were synthesized by a novel convergent route. Selectivity and efficacy versus MMPs and TACE could be controlled by appropriate substitution on the scaffolds and by variation of the P1′ group. Select compounds were found to be effective in in vivo models of arthritis.

N-Arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective α1-adrenoceptor antagonists

Novel arylpiperazines were identified as α1-adrenoceptor (AR) subtype- selective antagonists by functional in vitro screening. 3-[4-(ortho- Substituted phenyl)piperazin-1:yl]propylamines were derivatized with N,N- dimethyl anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4- b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta were used as a 'negative screen' for the test antagonists. Binding to α1-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure-affinity findings were exploited to produce nicotinamides (e.g. 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the α1-AR subtype prevalent in the human lower urinary tract (pA2 values: 8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2-3 orders of magnitude selectivity over the α(1D)-AR.